T2 Biosystems

T2 Biosystems is a developer of a next-generation medical diagnostic platform that enables rapid and accurate diagnostic tests of all types on a single instrument. With two FDA-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. Its initial development efforts target sepsis, hemostasis, bacteria and Lyme disease, which are areas of significant unmet medical need.

The Company is utilizing its proprietary T2 Magnetic Resonance platform to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.

Company Growth (employees)
Type
Public
HQ
Lexington, US
Founded
2006
Size (employees)
178 (est)+6%
T2 Biosystems was founded in 2006 and is headquartered in Lexington, US

Key People at T2 Biosystems

Tom Lowery

Tom Lowery

Vice President of Diagnostics Research & Development
Rahul Dhanda

Rahul Dhanda

Vice President of Global Support Services Marketing

T2 Biosystems Office Locations

T2 Biosystems has offices in Lexington and Wilmington
Lexington, US (HQ)
101 Hartwell Ave
Wilmington, US
231 Andover St

T2 Biosystems Data and Metrics

T2 Biosystems Financial Metrics

T2 Biosystems's revenue was reported to be $941 k in Q1, 2017
USD

Revenue (Q1, 2017)

941 k

EBIT (Q1, 2017)

(13.1 m)

Market capitalization (15-Aug-2017)

126.9 m

Cash (31-Mar-2017)

58.8 m
T2 Biosystems's current market capitalization is $126.9 m.
USDFY, 2014FY, 2015FY, 2016

Revenue

119 k2.8 m4.1 m

Revenue growth, %

2264%45%

R&D expense

19.8 m25.4 m24 m

General and administrative expense

11 m19.1 m24.1 m

Operating expense total

30.8 m46.2 m55 m

EBIT

(30.7 m)(43.4 m)(50.9 m)

EBIT margin, %

(25782%)(1542%)(1247%)

Interest expense

(721 k)(2 m)(4.1 m)

Net Income

(31.4 m)(45.3 m)(54.8 m)
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

188 k564 k1 m1.1 m990 k1.1 m941 k

R&D expense

5.9 m6.7 m6.2 m6.6 m6.4 m5.2 m6.6 m

General and administrative expense

4.5 m4.4 m5.2 m6.2 m6.1 m5.9 m5.9 m

Operating expense total

10.3 m11.1 m11.4 m12.8 m12.5 m11.1 m12.5 m

EBIT

(10.2 m)(10.5 m)(11.2 m)(12.7 m)(13.3 m)(11.9 m)(13.1 m)

EBIT margin, %

(5399%)(1866%)(1064%)(1161%)(1344%)(1102%)(1397%)

Interest expense

(477 k)(477 k)(501 k)(735 k)(805 k)(876 k)(1.6 m)

Net Income

(10.6 m)(11 m)(11.6 m)
USDFY, 2014FY, 2015FY, 2016

Cash

73.8 m73.7 m73.5 m

Accounts Receivable

201 k369 k327 k

Inventories

115 k683 k820 k

Current Assets

75.3 m75.6 m75.4 m

PP&E

2.8 m10.7 m13.6 m

Total Assets

79.1 m86.9 m89.6 m

Accounts Payable

735 k1.2 m962 k

Current Liabilities

5.2 m12.3 m9.9 m

Additional Paid-in Capital

156.6 m195.8 m243 m

Retained Earnings

(103.6 m)(148.9 m)(203.7 m)

Total Equity

53 m46.9 m39.3 m

Financial Leverage

1.5 x1.9 x2.3 x
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

65.3 m53.3 m40.1 m59.5 m50.2 m75.1 m58.8 m

Accounts Receivable

88 k389 k378 k360 k288 k379 k409 k

Inventories

252 k569 k1.1 m1.3 m1.4 m1.3 m489 k

Current Assets

66.4 m54.9 m42.7 m62 m52.5 m77.8 m60.7 m

PP&E

5.3 m7.8 m9.4 m12.3 m12.8 m13.6 m14.5 m

Total Assets

72.8 m63.7 m53.1 m74.9 m65.9 m92 m75.7 m

Accounts Payable

1.2 m1.6 m993 k1.6 m795 k895 k1.2 m

Current Liabilities

7.5 m7.7 m8.5 m14.7 m17.5 m18.5 m8.9 m

Additional Paid-in Capital

157.7 m159.2 m160.6 m197.4 m199 m239.7 m244.4 m

Retained Earnings

(114.2 m)(125.2 m)(136.9 m)(162.3 m)(176.4 m)(189.1 m)(218.4 m)

Total Equity

43.5 m34.1 m23.8 m35.1 m22.7 m50.6 m26 m

Financial Leverage

1.7 x1.9 x2.2 x2.1 x2.9 x1.8 x2.9 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(31.4 m)(45.3 m)(54.8 m)

Depreciation and Amortization

691 k1.5 m2.3 m

Accounts Receivable

(201 k)(168 k)42 k

Inventories

(1.2 m)(568 k)

Accounts Payable

(208 k)177 k(61 k)

Cash From Operating Activities

43.7 m(187 k)(46.4 m)

Purchases of PP&E

(2.1 m)(8 m)(5.5 m)

Cash From Investing Activities

(2.1 m)(7.9 m)(5.5 m)

Cash From Financing Activities

73.9 m45.2 m51.8 m

Interest Paid

515 k1.5 m2.7 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(10.6 m)(11 m)(11.6 m)

Accounts Receivable

88 k389 k378 k360 k288 k379 k409 k

Inventories

252 k569 k1.1 m1.3 m1.4 m

Accounts Payable

720 k725 k1.2 m1.6 m993 k1.6 m795 k895 k1.2 m
USDY, 2017

Revenue/Employee

5.6 k

Financial Leverage

2.9 x

T2 Biosystems Operating Metrics

T2 Biosystems's Patent Applications was reported to be 50 in FY, 2016
FY, 2016

Facilities

2

Patents Issued

50

Patent Applications

50

T2 Biosystems Market Value History

Traffic Overview of T2 Biosystems

T2 Biosystems Online and Social Media Presence

T2 Biosystems Company Life and Culture

You may also be interested in